Double-blind Comparative Study of TAK-875

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01433393

Enrollment

192

Registered

2011-09-14

Start date

Unknown

Completion date

2012-09-30

Last updated

2012-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Drug Therapy

Brief summary

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Interventions

DRUGPlacebo

DRUGTAK-875

Study design

Intervention model

PARALLEL

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Inclusion criteria

1. The participant is an outpatient. 2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease. 2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026